Breeze Holdings Acquisition CORP
Market Movers (8-K)
Breeze Holdings Acquisition Corp. stockholders have approved the business combination with YD Biopharma Limited, paving the way for the combined entity, YD Bio Limited, to trade on Nasdaq under the ticker YDES.
Breeze Holdings Acquisition Corp. shareholders approved an extension of the deadline to complete a business combination until September 26, 2025, amidst significant share redemptions and a reduced trust account balance.
Worse than expected
Capital raise
Delay expected
Breeze Holdings Acquisition Corp.'s publicly traded warrants and rights will transition from the OTCQX to the OTCQB market after failing to meet continued listing requirements, though its common stock remains on OTCQX and its business combination plans proceed.
Worse than expected
8-K: Breeze Holdings Acquisition Corp. Boosts PIPE Investment for YD Biopharma Merger to $30 Million
Breeze Holdings Acquisition Corp. announced an amendment to its merger agreement with YD Biopharma Limited, significantly increasing the Private Investment in Public Equity (PIPE) commitment from $15 million to $30 million.
Better than expected
Capital raise
Breeze Holdings Acquisition Corp. reported the immediate resignation of Bill Stark from its board of directors due to personal reasons, reducing the board size from seven to six members.
8-K: Breeze Holdings Acquisition Corp. Changes Accounting Firms: Marcum LLP Resigns, CBIZ CPAs Engaged
Breeze Holdings Acquisition Corp. announces the resignation of Marcum LLP as its independent registered accounting firm and the engagement of CBIZ CPAs P.C., effective April 2, 2025.
Quarterly Earnings (10-Q)
Breeze Holdings Acquisition Corp. reported a net loss of $5.58 million for the first half of 2025, while progressing towards its business combination with YD Biopharma and securing $13.2 million in PIPE financing.
Delay expected
Worse than expected
Capital raise
Breeze Holdings Acquisition Corp. reports a significant net loss and negative working capital, raising substantial doubt about its ability to continue as a going concern, despite securing an extension for its business combination deadline and identifying a new merger target, YD Biopharma Limited.
Worse than expected
Capital raise
Delay expected
Breeze Holdings Acquisition Corp. reported a net income of $2.19 million for the third quarter of 2024, while facing ongoing challenges related to its business combination and going concern status.
Worse than expected
Delay expected
Capital raise
Breeze Holdings Acquisition Corp. reported a net income of $17.1 million for the three months ended June 30, 2024, primarily driven by changes in the fair value of warrant liabilities, while facing ongoing challenges in completing a business combination.
Worse than expected
Delay expected
Capital raise
Breeze Holdings Acquisition Corp. reported a significant net loss for the first quarter of 2024, primarily due to changes in the fair value of warrant liabilities, while progressing towards its planned merger with True Velocity.
Worse than expected
Delay expected
Capital raise
Breeze Holdings Acquisition Corp. has filed an amendment to its quarterly report to correct an omission in the certification of its principal executive and financial officer.
Annual Reports (10-K)
10-K: Breeze Holdings Acquisition Corp. Faces Going Concern Uncertainty Amid Business Combination Pursuit
Breeze Holdings Acquisition Corp.'s 10-K filing reveals a company navigating financial uncertainties as it seeks a business combination, with a looming deadline and reliance on sponsor support.
Worse than expected
Capital raise
10-K/A: Breeze Holdings Files Amended 10-K to Include Internal Control Report and Correct Filing Error
Breeze Holdings Acquisition Corp. has filed an amendment to its annual report to include management's report on internal control over financial reporting and correct an erroneous reference.
Worse than expected
Capital raise
Breeze Holdings Acquisition Corp. files its annual 10-K report, outlining its financial status and the proposed business combination with True Velocity.
Worse than expected
Delay expected
Capital raise
10-K/A: Breeze Holdings Acquisition Corp. Files Amended 10-K to Correct Internal Control Certification
Breeze Holdings Acquisition Corp. has filed an amendment to its annual report to include a missing paragraph in the certification of internal control over financial reporting.
Delay expected
Capital raise
10-K/A: Breeze Holdings Acquisition Corp. Files Amended 10-K to Correct Internal Control Certification
Breeze Holdings Acquisition Corp. has filed an amendment to its annual report on Form 10-K to include a corrected certification regarding internal controls over financial reporting.
Insider Trading (Form 4)
Breeze Holdings Acquisition Corp. announced that its stockholders approved an extension of the deadline to complete an initial business combination until September 26, 2025, following a special meeting on June 26, 2025.
Capital raise
Delay expected
425: Breeze Holdings Acquisition Corp. Boosts PIPE Investment for YD Biopharma Merger to $30 Million
Breeze Holdings Acquisition Corp. announced an amendment to its merger agreement with YD Biopharma Limited, significantly increasing the Private Investment in Public Equity (PIPE) from $15 million to $30 million to support the proposed business combination.
Capital raise
Breeze Holdings Acquisition Corp. has successfully extended its deadline to complete a business combination to June 26, 2025, following a shareholder vote on December 23, 2024.
Delay expected
Breeze Holdings Acquisition Corp. and YD Biopharma Limited have entered into a definitive agreement for a business combination, valuing the combined entity at nearly $700 million, with plans to list on the Nasdaq Capital Market.
Capital raise
Breeze Holdings Acquisition Corp. has terminated its merger agreement with TV Ammo, ceasing pursuit of the business combination.
Worse than expected
Breeze Holdings Acquisition Corp. successfully extends the deadline for completing a business combination to December 26, 2024, following a special meeting of stockholders.
Delay expected
Proxy Statements (Def-14A)
Breeze Holdings Acquisition Corp. has filed a supplement to its definitive proxy statement to correct an error in the proxy card for its upcoming Special Meeting, requiring shareholders to resubmit votes.
DEFM14A: Breeze Holdings and YD Biopharma to Merge, Creating Nasdaq-Listed Biopharmaceutical Company
Breeze Holdings Acquisition Corp. (BRZH) will merge with YD Biopharma Limited, valuing the combined entity at \$688.3 million, with the resulting company to be listed on The Nasdaq Capital Market under the ticker symbol "YDES".
Delay expected
Capital raise
DEF: Breeze Holdings Seeks Extension for Biopharma Merger Amid Nasdaq Delisting and Liquidation Risks
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend its business combination deadline until September 26, 2025, to facilitate its proposed merger with Taiwan-based YD Biopharma Limited, following its delisting from Nasdaq.
Delay expected
Worse than expected
Capital raise
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination by up to six months, with a special meeting scheduled for December 23, 2024.
Delay expected
Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination, primarily to finalize its merger with TV Ammo.
Delay expected
Schedule 13G - Passive Investments
SCHEDULE 13G/A: Cowen Financial Products Reports Zero Beneficial Ownership in Breeze Holdings Acquisition Corp
Cowen Financial Products LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Breeze Holdings Acquisition Corp's common stock.